• Contact: +91-9643310025, 9643312749
  • Generic selectors
    Exact matches only
    Search in title
    Search in content
    Search in posts
    Search in pages
    Filter by Categories
    Annual brand plans
    Autoimmune diseases
    Conference support
    Corporate strategy and R & D consulting
    KOL support
    MSL training
    Orphan Diseases
    Pre-& post launch activities
    Sales & marketing
    Sales force training

Duchenne Muscular Dystrophy (DMD) Pipeline Dashboard, H1 2018

Scope of report

  • The report provides a snapshot of the global therapeutic landscape of Duchenne Muscular Dystrophy.
  • The report assesses Duchenne Muscular Dystrophy pipeline based on highest phase of development, type of sponsor, mechanism of action (MoA), route of administration (RoA), and molecule type.
  • The report reviews Duchenne Muscular Dystrophy pipeline by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The report covers pipeline products based on various stages of development for Duchenne Muscular Dystrophy ranging from discovery to pre-registration and undisclosed stages.

Companies Covered:

FibroGen, Collgard Biopharmaceuticals, ProSkelia, GTx; Merck & Co, ViroMed Co Ltd, PTC Therapeutics, VASTox, Asklepios BioPharmaceutical, Prosensa, AVI BioPharma, Ercole Biotech, Acceleron Pharma, Amsterdam Molecular Therapeutics, Beike Biotechnology, Catabasis Pharmaceuticals, Tarix Pharmaceuticals, Karyopharm Therapeutics, Phrixus Pharmaceuticals, ReveraGen BioPharma, Retrophin, Pfizer

Key Drugs:

Pirfenidone, Pamrevlumab, AEOL 10150, Sonolisib, Nintedanib, Tipelukast, Lebrikizumab, STX 100, Carlumab, Dectrekumab, Tanzisertib, PBI 4050, PRM 151, Omipalisib

Publisher: Pharmintel

Format: Microsoft Excel
Sheets: 8

  • Single Use:  $300
  • Site License: $500
  • Global License: $800

Report Inquiry

Leave a Reply

Your email address will not be published. Required fields are marked *

+91 9643310025, 9643312749
© 2024 Pharmintel